Exact Sciences' Earnings Hammer Short-Sellers (Again)
Americans have historically done poorly when it comes to sticking to recommended guidelines for colon cancer screening, but a new test launched by Exact Sciences (NASDAQ: EXAS) may be changing that -- and frustrating short-sellers in the process.
Bears have been lining up against Exact Sciences since Cologuard's launch, arguing that the test isn't nearly as useful as a colonoscopy and that doctors and patients will shun it. So far, that hasn't been the case, and as a result, short-sellers have been forced to cover their position in Exact Sciences, pushing shares higher.
Image source: Getty Images.
Source: Fool.com
Exact Sciences Aktie
60,89 €
3,06 %
Mehrere Buy-Einschätzungen geben Exact Sciences den Vorteil, ohne Sell-Einschätzungen.
Das Community-Kursziel von 76 € für Exact Sciences deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 60.89 € hin.
